ventures
Neuroscience therapeutics, including the deuterated psilocin analog CYB003, Focus:
to transform treatment for major
Psychedelics depressive disorder - Phase II (Depression, Preclinical Phase 1
University of Nottingham spinout developing small-molecule modulators of mRNA splicing to treat wet AMD and diabetic macular oedema, in collaboration with Janssen (J&J) - Phase II Inception
Small Molecule
Small Molecule
IPO - Exited to Cybin Inc. NYSE listed $425M
Dermatology therapeutics targeting stop codon mutations in cancer and Focus: Discovery Preclinical Phase 1genetic diseases through strategicPhase 2
Depression & PainPlatform Platform Platform Area: CNS / Platform Neuroscience Platform Focus:Platform PsychiatricCRO (Schizophrenia, PlatformPlatform Depression)
Developing oral, abuse-deterrent ketamine formulations (Keticap) for treating depression, bipolar disorder, and other mood-related conditions - Phase II Inception
Advancing precision psychiatry and neurology through digital biomarkers and novel CNS compounds to deliver targeted treatments for defined patient subtypes - Phase I